|
Mediatora
|
Indirect Effect
|
Bootstrap Bias Corrected 95% CI for Indirect Effect
|
Direct Effect
|
% Effect Mediated
|
Sobel p-value
|
|---|
|
A. Airflow obstruction (FEV1/FVC) and CAC
|
|
MMP3 (ng/mL)
|
−0.061
|
−0.126 to − 0.022
|
−0.662
|
8.5
|
0.015
|
|
VCAM1 (ng/mL)
|
−0.057
|
−0.134 to − 0.020
|
−0.666
|
7.9
|
0.019
|
|
CXCL9 (pg/mL)
|
−0.114
|
−0.194 to − 0.057
|
−0.609
|
15.8
|
< 0.001
|
|
CXCL5 (ng/mL)
|
−0.049
|
−0.102 to − 0.015
|
−0.673
|
6.8
|
0.040
|
|
B. Centrilobular Emphysema and CAC
|
|
MMP3 (ng/mL)
|
0.019
|
0.006 to 0.042
|
0.226
|
7.9
|
0.033
|
|
VCAM1 (ng/mL)
|
0.018
|
0.004 to 0.041
|
0.227
|
7.3
|
0.041
|
|
CXCL9 (pg/mL)
|
0.042
|
0.022 to 0.074
|
0.203
|
17.0
|
0.001
|
- CAC Coronary artery calcification, FEV1 Forced expiratory volume in the first second, FVC Forced vital capacity, MMP3 Matrix metalloproteinase 3. VCAM1 = Vascular cell adhesion molecule 1. CXCL = C-X-C Motif Chemokine Ligand
- aAll mediators were log transformed prior to analysis
